RB1 and acute lymphoblastic leukemia: Interestingly, RB1 hypophosphorylation occurring upon treatment with glucocorticoids, the main pharmacological agents used against childhood acute lymphoblastic leukemia (ALL), correlates with a good responsiveness [115], suggesting that RB1 might represent a possible surrogate endpoint of therapeutic response for childhood ALL.